Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.59 |
| ▸ | TERT | O14746 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25318421 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL25320538 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL25315545 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL25316108 | 1.00 | TBXAS1 (0.59) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL181392 | 0.98 | TBXAS1 (0.56) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL181705 | 0.92 | — | — | |
| SCHEMBL28062565 | 0.89 | TBXAS1 (0.69) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL503743 | 0.89 | TBXAS1 (0.69) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL3431746 | 0.87 | TBXAS1 (0.66) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL181657 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421954-B2 | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (US) | 2019-09-24 | — | — | US | claimed |
| US-9969773-B2 | Polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (US) | 2018-05-15 | — | — | US | claimed |
| US-20170015991-A1 | HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | NEW YORK UNIVERSITY | 2017-01-19 | — | — | US | claimed |
| US-9458449-B2 | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (US) | 2016-10-04 | — | — | US | claimed |
| US-20150044189-A1 | HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | NEW YORK UNIVERSITY | 2015-02-12 | — | — | US | claimed |
| US-20150011465-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY | 2015-01-08 | — | — | US | claimed |
| US-8828413-B2 | Peptoid oligomers, pharmaceutical compositions and methods of using the same | NEW YORK UNIVERSITY (US) | 2014-09-09 | — | — | US | claimed |
| EP-2401264-A2 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | New York University (US) | 2012-01-04 | — | — | EP | claimed |
| WO-2011156003-A2 | PEPTOID AND SYNTHETIC OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2011-12-15 | — | — | WO | claimed |
| WO-2010098843-A2 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY (US) | 2010-09-02 | — | — | WO | claimed |
| US-20240165245-A1 | MULTIVALENT PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2024-05-23 | — | — | US | disclosed |
| US-20230303404-A1 | NANOPARTICLES, DISPERSION OF NANOPARTICLES, AND PRODUCTION METHOD OF NANOPARTICLES | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11766480-B2 | Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same | NEW YORK UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230242692-A1 | COMPOSITION AND CURED PRODUCT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| CN-116515023-A | Composition and cured product | 东京应化工业株式会社 | 2023-08-01 | — | — | CN | disclosed |
| WO-1995000468-A1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-05 | — | — | WO | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| EP-0612319-A1 | BENZOHETEROCYCLIC COMPOUNDS AS OXYTOCIN AND VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-31 | — | — | EP | disclosed |
| CN-1090576-A | Benzoheterocyclic compounds | OTSUKA PHARMA CO LTD (JP) | 1994-08-10 | — | — | CN | disclosed |
| WO-1994004525-A1 | BENZOHETEROCYCLIC COMPOUNDS AS OXYTOCIN AND VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011465-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NOD2, VIP, NOD1 | TBXAS1 1582/4885TERT 2224/4885ALOX15 637/4885 |
| US-10421954-B2 | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | F12, RPS4Y1, NPY1R | TBXAS1 635/4885TERT 1932/4885ALOX15 3574/4885 |
| US-20240165245-A1 | MULTIVALENT PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | AR, SHBG, KLK3 | TBXAS1 1008/4885TERT 3296/4885ALOX15 1525/4885 |
| US-20170015991-A1 | HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | F12, RPS4Y1, NPY1R | TBXAS1 635/4885TERT 1932/4885ALOX15 3574/4885 |
| US-20230303404-A1 | NANOPARTICLES, DISPERSION OF NANOPARTICLES, AND PRODUCTION METHOD OF NANOPARTICLES | CD63, NIBAN2, ZRANB2 | TBXAS1 1738/4885TERT 1995/4885ALOX15 2114/4885 |
| US-11766480-B2 | Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same | AR, SHBG, KLK3 | TBXAS1 1008/4885TERT 3296/4885ALOX15 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.